Drugs Made In America Acquisition Corp. DMAA
$10.80
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 136.90K | 143.30K | 2.09M | 263.70K | 131.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.90K | 143.30K | 2.09M | 263.70K | 131.90K |
| Operating Income | -136.90K | -143.30K | -2.09M | -263.70K | -131.90K |
| Income Before Tax | 1.73M | 1.97M | 213.00K | 2.18M | 2.29M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.73M | 1.97M | 213.00K | 2.18M | 2.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.73M | 1.97M | 213.00K | 2.18M | 2.29M |
| EBIT | -136.90K | -143.30K | -2.09M | -263.70K | -131.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.06 | 0.06 | 0.01 | 0.07 | 0.07 |
| Normalized Basic EPS | 0.04 | 0.04 | 0.00 | 0.04 | 0.04 |
| EPS Diluted | 0.06 | 0.06 | 0.01 | 0.07 | 0.07 |
| Normalized Diluted EPS | 0.04 | 0.04 | 0.00 | 0.04 | 0.04 |
| Average Basic Shares Outstanding | 30.81M | 33.72M | 34.19M | 33.52M | 33.52M |
| Average Diluted Shares Outstanding | 30.81M | 33.72M | 34.19M | 33.52M | 33.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |